About Sandostatin LAR® Depot

Launched in the U.S. by Novartis in 1999, Sandostatin LAR® Depot (octreotide acetate for injectable suspension) is a once-monthly injection that reduces and normalizes levels of hormone hypersecretion in many patients with acromegaly, carcinoid syndrome, and VIPomas.

In this section, learn about:

trst..;xcvxd
Adjust Text Size of Sandostatin LAR Depot (octreotide acetate)Small Text for Sandostatin LAR Depot (octreotide acetate)Medium Text for Sandostatin LAR Depot (octreotide acetate)Large Text for Sandostatin LAR Depot (octreotide acetate)
US Sandostatin Home | For Healthcare Professionals
About Sandostatin | Acromegaly | Carcinoid Syndrome & VIPomas | Reimbursement & Acquisition | Resources
Prescribing Information | Important Information | Site Map | Contact Us | Sites For Patients: AcromegalyInfo.com | Carcinoid.com